EP1858488B1 - Tigecyclin-zusammensetzungen und herstellungsverfahren dafür - Google Patents

Tigecyclin-zusammensetzungen und herstellungsverfahren dafür Download PDF

Info

Publication number
EP1858488B1
EP1858488B1 EP06737947.9A EP06737947A EP1858488B1 EP 1858488 B1 EP1858488 B1 EP 1858488B1 EP 06737947 A EP06737947 A EP 06737947A EP 1858488 B1 EP1858488 B1 EP 1858488B1
Authority
EP
European Patent Office
Prior art keywords
tigecycline
lactose
solution
composition
lyophilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP06737947.9A
Other languages
English (en)
French (fr)
Other versions
EP1858488A1 (de
EP1858488B2 (de
Inventor
Mahdi B. Fawzi
Tianmin Zhu
Syed M. Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36648809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1858488(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to SI200631658T priority Critical patent/SI1858488T2/sl
Priority to PL06737947.9T priority patent/PL1858488T5/pl
Publication of EP1858488A1 publication Critical patent/EP1858488A1/de
Publication of EP1858488B1 publication Critical patent/EP1858488B1/de
Priority to CY20131100905T priority patent/CY1114504T1/el
Application granted granted Critical
Publication of EP1858488B2 publication Critical patent/EP1858488B2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to improved tigecycline compositions and methods for making such compositions.
  • the inventive compositions have improved stability in both solid and solution states.
  • the inventive compositions comprise tigecycline, a suitable carbohydrate as defined herein, and an acid or buffer wherein the pH of the composition is between 3.0 and 7.0.
  • the combination of the suitable carbohydrate and the acid or buffer reduces tigecycline degradation as explained below.
  • the present invention provides advantages over the prior art by providing for stable tigecycline compositions and methods for making such compositions that achieve stability against both oxidative degradation and epimerization. These compositions are, therefore, more stable when dissolved, lyophilized, reconstituted, and/or diluted than compositions of tigecycline not made according to the invention.
  • Tigecycline is a known antibiotic in the tetracycline family and a chemical analog of minocycline. It may be used as a treatment against drug-resistant bacteria, and it has been shown to work where other antibiotics have failed. For example, it is active against methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pnaumoniae, vancomycin-resistant enterococci ( D.J. Maschinennbach et. al., Diagnostic Microbiology and Infectious Disease 40:173-177 (2001 ); H.W. Boucher et. al., Antimicrobial Agents & Chemotherapy 44:2225-2229 (2000 ); P.A. Bradford Clin. Microbiol. Newslett.
  • Tigecycline has historically been administered intravenously because it exhibits generally poor bioavailability when given orally.
  • Gopal Muralidharan et al., Antimicrobial Agents & Chemotherapy 49:220-229 describe the pharmacokinetic behaviour of tigecycline after reconstitution from lyophilized powder.
  • Intravenous solutions have largely been prepared immediately prior to use, e.g., administration to a patient, from lyophilized powders because tigecycline degrades in solution principally via oxidation. It would be preferable as well as desirable to have an intravenous formulation of tigecycline that did not require immediate use and could remain stable in solution for up to 24 hours.
  • Tigecycline is currently manufactured as a lyophilized powder. Due to the propensity for tigecycline to degrade, these powders are prepared under low-oxygen and low-temperature conditions in order to minimize degradation. Such processing is expensive because it requires special equipment and handling.
  • the typical process for preparing these powder compositions involves dissolving tigecycline in water (compounding) and lyophilizing (freeze-drying) the solution to dryness to form solid cakes of amorphous tigecycline. These cakes are then loaded under nitrogen into stoppered glass vials and shipped to end users such as hospital pharmacies. Prior to being administered to patients, the cakes are reconstituted, often in 0.9% saline, to a concentration of, for example, about 10 mg/mL. At this concentration, tigecycline degrades rapidly in solution and therefore, must be used without delay. Thus, these reconstituted solutions are immediately diluted (also known as admixing) to about 1 mg/mL with saline or other pharmaceutically acceptable diluents into intravenous bags for patient delivery.
  • tigecycline is ready for intravenous delivery to a patient.
  • tigecycline should be used within 6 hours of dilution. Because intravenous infusions may take several hours, hospital personnel must act quickly so that from the time admixture begins to the time the tigecycline dose has been administered to a patient, not more then 6 hours have elapsed. It would be more preferred to provide hospital staff with the flexibility and advantages that come with longer admixture and reconstitution times so that, for instance, a hospital pharmacist could prepare a solution the day before it is needed to be administered to a patient.
  • Tigecycline has such a short admixture time and the reconstitution time is essentially zero because in solution, tigecycline oxidation is relatively rapid. Under current manufacturing, storage, and administration conditions, the most prevalent form of degradation is via oxidation. The reason oxidation is the most prevalent form of degradation in previous formulations relates to the chemical structure of tigecycline. It possesses a phenol moiety, and it is well known in the art of organic chemistry that phenols are particularly prone to oxidation. When tigecycline is dissolved in water prior to lyophilization, the pH is slightly basic (about 7.8). This is higher than the pKa of the phenolic group on tigecycline.
  • tigecycline solution were less than the pKa of the phenolic group on tigecycline, then oxidation would occur, but to a lesser extent. Indeed, it has been observed that tigecycline oxidative degradation does decrease when the pH is lowered. At low pH, however, another degradative process occurs, epimerization. At lower pHs, epimerization emerges as the most predominant degradation pathway.
  • Tigecycline differs structurally from its epimer in only one respect.
  • tigecycline the N-dimethyl group at the 4 carbon is cis to the adjacent hydrogen as shown above in formula I, whereas in the epimer, formula II, they are trans to one another in the manner indicated.
  • the tigecycline epimer is believed to be non-toxic, it lacks the anti-bacterial efficacy of tigecycline and is, therefore, an undesirable degradation product.
  • tigecycline follows the same degradation pathways as in solution, but the rate of degradation is slower.
  • the resulting lyophilized cake exhibits oxidative degradation, albeit at a slower rate than in solution.
  • the primary degradation pathway is epimerization and it also occurs at a slower rate than in solution.
  • Epimerization is a known degradation pathway in tetracyclines generally, although the rate of degradation may vary depending upon the tetracycline. Comparatively, the epimerization rate of tigecycline is particularly fast.
  • the tetracycline literature reports several methods scientists have used to try and minimize epimer formation in tetracyclines. In some methods, the formation of calcium, magnesium, zinc or aluminum metal salts with tetracyclines limit epimer formation when done at basic pHs in non-aqueous solutions. ( Gordon, P.N, Stephens Jr, C.R., Noseworthy, M. M., Teare, F.W., U.K. Patent No. 901,107 ). In other methods, ( Tobkes, U.S. Patent No. 4,038,315 ) the formation of a metal complex is performed at acidic pH and a stable solid form of the drug is subsequently prepared.
  • Tetracycline epimerization is also known to be temperature dependent so production and storage of tetracyclines at low temperatures can also reduce the rate of epimer formation ( Yuen, P.H., Sokoloski, T.D., J. Pharm. Sci. 66: 1648-1650,1977 ; Pawelczyk, E., Matlak, B, Pol. J. Pharmacol. Pharm. 34: 409-421, 1982 ).
  • tigecycline Several of these methods have been attempted with tigecycline but none have succeeded in reducing both epimer formation and oxidative degradation while not introducing additional degradants. Metal complexation, for example, was found to have little effect on either epimer formation or degradation generally at basic pH.
  • phosphate, acetate, and citrate buffers improve solution state stability, they seem to accelerate degradation of tigecycline in the lyophilized state. Even without a buffer, however, epimerization is a more serious problem with tigecycline than with other tetracyclines such as minocycline.
  • minocycline could be combined with an acid to increase the stability toward the oxidative degradation. It further discloses the use of a caking agent, such as mannitol.
  • a caking agent such as mannitol.
  • This reference says nothing about tigecycline nor does it suggest that carbohydrates could be used to reduce either oxidation or epimerization for minocycline in reduced pH environments.
  • minocycline can be formulated as a hydrochloride salt in intravenous products without significant epimerization. In tigecycline hydrochloride salts, however, significant epimerization occurs. Thus, minocycline and tigecycline possess different epimerization properties.
  • minocycline was lyophilized at a pH of about 5.0 and the lyophilized cake was stored for 20 days at 40°C and 75% relative humidity. At the end of the 20 days, the cake was analyzed by HPLC. The epimer of minocycline was measured to be present at a level of 2.65% by mass.
  • the tigecycline epimer was measured to be at a level of 5.40%, over twice as much even though tigecycline was only stressed for 1/5th as long as minocycline.
  • the present invention addresses the various problems and disadvantages of the prior art by providing for stable compositions of tigecycline in solid and solution form.
  • aqueous solution containing tigecycline and a suitable carbohydrate as defined herein at an acidic pH between 3.0 and 7.0, we have prepared tigecycline compositions that are more stable against both oxidative degradation and epimerization than existing compositions. Because the pH is acidic, oxidative degradation has been minimized. Furthermore, it has been determined that suitable carbohydrate as defined herein act to stabilize tigecycline against epimer formation at acidic pHs.
  • compositions of the invention are more stable in the lyophilized state than the existing compositions and do not require low-temperature or low-oxygen processing conditions. Such compositions are also expected to possess reconstitution and admixture stability times greater than that of the existing compositions. For example, one embodiment of the invention is stable for 6 hours after reconstitution and stable for an additional 18 hours after admixture. These extended stability times make tigecycline much easier to use in a hospital environment by providing needed flexibility to hospital staff when treating patients.
  • Solid-state compositions of the invention comprise tigecycline, a suitable carbohydrate as defined herein, and an acid or buffer wherein the pH of the composition is between 3.0 and 7.0.
  • Suitable carbohydrates as defined herein are capable of reducing epimer formation in at least one solid form prepared in at least one pH environment when compared to a tigecycline solid form prepared at the same pH environment lacking suitable carbohydrates.
  • the pH environment ranges from 4.0 to 5.0, or from 4.2 to 4.8.
  • the at least one solid form is chosen from powders and lyophilized cakes of tigecycline.
  • Suitable carbohydrates are the anhydrous, hydrated, and solvated forms of lactose, mannose, sucrose, and glucose. Suitable carbohydrates are preferably lactose and sucrose. Lactose is most preferred. Accordingly, suitable carbohydrates may include different solid forms.
  • lactose we include the different solid forms of lactose such as anhydrous lactose, lactose monohydrate or any other hydrated or solvated form of lactose. Lactose and sucrose are disaccharides.
  • compositions of the invention include solutions, such as those prepared prior to lyophilization, containing tigecycline, a suitable carbohydrate, and an acid or buffer. In some embodiments of the invention, the solutions may be stored for several hours prior to lyophilization in order to provide greater manufacturing flexibility.
  • compositions of the invention further include lyophilized powders or cakes containing tigecycline, a suitable carbohydrate, and an acid or buffer wherein the pH of the composition is between 3.0 and 7.0.
  • the suitable carbohydrate used is lactose monohydrate and the molar ratio of tigecycline to lactose monohydrate in the lyophilized powder or cake is between about 1:0.2 to about 1:5. Some embodiments have tigecycline to lactose monohydrate molar ratios of between about 1:1.6 to about 1:3.3.
  • compositions of the invention also include solutions made from the lyophilized powder or cake by, for example, reconstitution with saline or other pharmaceutically acceptable diluents.
  • compositions of the invention further include solutions resulting from diluting those reconstituted solutions with pharmaceutically acceptable diluents for use in intravenous bags.
  • Acids and buffers of the invention include any pharmaceutically acceptable acid or buffer capable of adjusting the pH of a tigecycline/suitable carbohydrate solution to between about 3.0 to about 7.0, about 4.0 to about 5.0, or about 4.2 to about 4.8.
  • acids include, but are not limited to, hydrochloric acid, including 1.0 N HCl, gentisic acid, lactic acid, citric acid, acetic acid, and phosphoric acid.
  • suitable buffers include succinates.
  • tigecycline is dissolved in water to form a solution.
  • the pH of the solution is subsequently lowered to between 3.0 and 7.0 by addition of an acid or buffer.
  • a suitable carbohydrate as defined herein is then dissolved in the solution and the solution is lyophilized to dryness to form a lyophilized powder or cake.
  • Tigecycline may be blended with a suitable carbohydrate as defined herein and dissolved in water. After the pH of the solution is adjusted to between 3.0 and 7.0 so that it is acidic, the solution may then be lyophilized to dryness to form a lyophilized powder or cake.
  • Lyophilization of solutions of the invention may be accomplished by any pharmaceutically acceptable means. Once lyophilized, compositions of the invention may be stored under an inert gas, such as nitrogen, to further slow the degradation process, but, unlike the current tigecycline composition, such low oxygen environments are not necessary for the invention.
  • an inert gas such as nitrogen
  • any solid-state form of tigecycline that is sufficiently soluble in water may be used.
  • Such solid-state forms include crystalline tigecycline polymorphs, amorphous forms, and salts.
  • tigecycline solutions of the invention when preparing tigecycline solutions of the invention for lyophilization, one adds sufficient acid or buffer to the aqueous solution containing tigecycline to obtain a pH from about 3.0 and about 7.0 including from about 4.0 to about 5.0 and from about 4.2 to about 4.8.
  • compositions of the invention may be prepared for single-dosage use.
  • the solutions of the invention are lyophilized in individual vials, such as 20 ml vials. Upon lyophilization, the vials are stoppered with any pharmaceutically acceptable stopper. The stoppered vials are then shipped for use.
  • the vials can be reconstituted by adding sufficient diluent to achieve the desired concentration of tigecyclirie.
  • concentration of reconstituted solutions may be easily determined by those of ordinary skilled in the art.
  • Any pharmaceutically acceptable diluents may be used. Examples of such diluents include water, saline, such as 0.9% saline, Lactated Ringer's Injection solution and dextrose solutions including 5% dextrose (D5W).
  • Reconstituted solutions of the invention may then be stored in a reconstituted state, unlike current compositions, prior to admixture.
  • Admixture can occur, for example, in an intravenous bag.
  • a pharmaceutically acceptable diluent such as saline solution or dextrose solution such as D5W.
  • concentration of admixtures may be easily determined by those of ordinary skill in the art. Admixture times for compositions of the invention can be much longer than those of the existing composition.
  • the tigecycline solution is ready for patient administration.
  • the admixture may be administered alone or together with another pharmaceutical agent or composition.
  • solutions of tigecycline, lactose, and 1.0 N HCl were lyophilized and the resulting cakes were placed in stability chambers at 40°C and 75% relative humidity for 25 days. At the end of the 25 days, the cakes were analyzed by HPLC to identify degradation products.
  • Example 2a A similar experiment is detailed in Example 2a. There, the lyophilized cakes were analyzed by HPLC after being stored for 39 days at 40°C and 75% relative humidity. Sample cakes from two of the experiments were reconstituted in D5W (5% dextrose) and samples from the remaining cakes were reconstituted in saline immediately prior to HPLC analysis.
  • D5W 5% dextrose
  • Example 2c illustrates a stability test on admixed solutions.
  • the reconstituted solutions of example 2b were held for 6 hours at about 10 mg/mL and then diluted to about 1 mg/mL, the typical intravenous concentration for tigecycline, and held for 18 hours prior to analysis by HPLC (table 2c).
  • gentisic acid rather than hydrochloric acid, was used to reduce the pH of the pre-lyophilized solutions of tigecycline. Once lyophilized, the cakes were stressed at 45°C and 75% relative humidity for 48 days and then analyzed by HPLC.
  • example 4 show the effects of changing from lactose to other carbohydrates on epimer formation and tigecycline recovery when making the pre-lyophilized tigecycline solutions.
  • the indicated solutions were prepared and lyophilized.
  • Each cake was stressed according to the parameters provided in examples 4a-4c, taken into solution, and analyzed by HPLC.
  • the ratio of lactose to tigecycline was varied in the experiments in example 6.
  • varying ratios of lactose to tigecycline were employed.
  • the mass ratios are reported in the first column of table 6.
  • the solutioris, which each had a pH of about 5.0, were subsequently lyophilized to dryness and the resulting cakes were stressed at 40°C and 75% relative humidity for 20 days and analyzed by HPLC.
  • Tigecycline (1880 mg) was dissolved in 75ml of Milli-Q water to form a bulk solution. An aliquot from this bulk solution containing approximately 100 mg of tigecycline was dissolved into a 20 ml vial containing 200 mg of lactose monohydrate. Another aliquot of the bulk solution containing approximately 100 mg of tigecycline was placed into an empty 20 ml sample vial. No pH adjustment was made to either of these two solutions. The solutions were subsequently lyophilized to dryness.
  • the pH of the remaining bulk solution was lowered to about 6.0 with the addition of 1.0N HCl. Once a pH of about 6.0 was obtained, an aliquot from the bulk solution containing about 100 mg of tigecycline was dissolved into a 20 ml sample vial containing about 200 mg of lactose monohydrate and the resulting solution was lyophilized to dryness. The remaining bulk solution was treated with 1.0N HCl until a pH of about 5.5 was obtained at which point 100 mg of tigecycline from the bulk solution was transferred into a 20 ml vial containing 200 mg of lactose monohydrate. After dissolution, the solution was lyophilized to dryness.
  • compositions of the invention are apparent from this example. For instance, in the composition prepared without lactose at a pH of about 4.5, only 74.10% tigecycline was detected whereas the epimer was present in an amount of 23.51 %. By comparison, the pH 4.5 sample with lactose contained only 2.53% epimer and had a tigecycline content of 97.17%.
  • Tigecycline (1700mg) was dissolved in 85ml of Milli-Q water to form a bulk solution.
  • Solutions containing about 100 mg of tigecycline and about 200 mg of lactose monohydrate were prepared at pHs of about 5.2, 5.0, 4.8, and 3.0 in the same manner that tigecycline/lactose/HCl solutions were prepared in example 1.
  • a solution of tigecycline and lactose at pH of about 4.5 was prepared by adding 1.0 N NaOH to the bulk solution at pH 3.0 followed by dissolving an aliquot of bulk solution containing about 100 mg of tigecycline into a 20 ml vial containing about 200 mg of lactose monohydrate.
  • Example 2b At the end of 39 days, the lyophilized cakes of Example 2a were reconstituted with 0.9% NaCl to a concentration of 10 mg/ml of tigecycline and kept at room temperature for 6 hours. Separate aliquots of the solutions at pH of about 5.0 and about 4.5 were reconstituted with 5% Dextrose, instead of saline, to a concentration of about 10mg/ml and kept at room temperature for 6 hours. Each of the solutions was then analyzed by HPLC, and the results are shown in Table 2b.
  • compositions of the invention protect against epimer formation in reconstituted solutions for 6 hours. Indeed, the maximum epimer content of any one of these examples was only 2.45%, whereas the minimum tigecycline content was 97.1 %.
  • the pH was about 4.5 and the diluent was saline, at the end of the 6 hour reconstitution period, only 1.60% of epimer was present. In that embodiment, the amount of tigecycline was measured to be 98.15%, which, in some applications, may be of sufficient purity for hospital use.
  • Admixture solutions of tigecycline (at 1 mg/ml) were made by diluting the reconstituted solution (from example 2b) with 0.9% NaCl or 5% Dextrose depending upon which diluent was used for reconstitution. The solutions were then kept at room temperature for 18 hours and analyzed by HPLC. The results are summarized in Table 2c.
  • Tigecycline 700mg was dissolved in 28ml of Milli-Q water to form a bulk solution. An aliquot of the bulk solution containing about 100 mg of tigecycline was loaded into a 20 ml vial as control sample. Solution samples of tigecycline, lactose, and an acid were prepared at pHs of about 5.8, 5.1, and 4.5 according to the methods of example 1 except that gentisic acid was used to lower the pH of the bulk solution rather than 1.0 N HCl. An additional two samples of tigecycline solutions without lactose were prepared, one at a pH of about 5.1 and another at a pH of about 4.5.
  • Tigecycline (1600mg) was dissolved in 64ml of Milli-Q water to form a bulk solution and two samples from the solution, each containing about 100 mg of tigecycline, were loaded into two separate sample 20 ml sample vials containing 160 mg of lactose monohydrate and 160 mg mannitol respectively.
  • a third sample containing about 100 mg of tigecycline from the bulk solution was loaded into a blank 20 ml vial.
  • the pH of the remainder of the bulk solution was sequentially adjusted with 1.0N HCl to about 7.0, 6.5, and 6.0 as per the procedure outlined in example 1.
  • Sample solutions each containing about 100 mg tigecycline were loaded into 20 ml vials containing 160 mg of lactose monohydrate, 160 mg of mannitol, or neither at each pH value.
  • the resulting solutions were lyophilized (frozen at -70°C by dry ice with acetone) to dryness.
  • the lyophilized samples were placed in a 40°C oven for 70 hours and then analyzed by HPLC. The data are summarized in table 4a.
  • Tigecycline (1800mg) was dissolved in 72ml of Milli-Q water to form a bulk solution. Aliquots from the bulk solution containing about 100 mg of tigecycline were loaded into three separate 20 ml vials containing about 200 mg of lactose monohydrate, fructose, and sucrose respectively. The pH of the bulk solution was sequentially adjusted with 1.0N HCl to about 6.0 and 5.4 according to the procedure outlined in example 1. At each pH value, aliquots of solution containing about 100 mg of tigecycline were taken into 20 ml vials containing 200mg of one of the following carbohydrates: lactose monohydrate, fructose, or sucrose and dissolved. Solutions without carbohydrates were also prepared at each pH value.
  • Tigecycline 1000mg was dissolved in 50ml of Milli-Q water to form a bulk solution. The pH of the bulk solution was adjusted with 1.0N HCl to about 5.0. Four aliquots of bulk solution, each containing about 100 mg of tigecycline, were loaded into 20 ml vials containing about 200 mg of glucose, mannose, ribose, and xylose respectively and dissolved. A fifth aliquot of bulk solution containing about 100 mg of tigecycline was loaded into a 20 ml vial containing about 125mg of threose and dissolved. All five solutions were lyophilized (frozen at -50°C by freeze dryers from AdVantage/Virtis) to dryness.
  • Lactose monohydrate 750 mg was dissolved in 15ml of Milli-Q water. Tigecycline (375mg) was added to this solution and the pH was adjusted to about 5.0 with 1.0N HCl. At this pH, two aliquots from the solution, each containing about 100 mg of tigecycline and about 200 mg of lactose monohydrate, were loaded into two 20 ml vials respectively. The solution in one sample vial was frozen immediately at -70°C (by dry ice with acetone). The solution in the other sample was kept at room temperature for 5 hours before freezing. Frozen samples were lyophilized to dryness. The lyophilized samples were placed in a 40°C/75%RH chamber for 48 days and analyzed by HPLC.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (17)

  1. Zusammensetzung, umfassend:
    (a) Tigecyclin;
    (b) ein Kohlenhydrat, ausgewählt aus Laktose, Mannose, Saccharose und Glukose, und
    (c) eine Säure oder einen Puffer,
    wobei der pH der Zusammensetzung zwischen 3,0 und 7,0 ist.
  2. Zusammensetzung gemäß Anspruch 1, wobei das Kohlenhydrat Laktose ist.
  3. Zusammensetzung gemäß einem der Ansprüche 1 bis 2, wobei die Zusammensetzung lyophilisiert ist.
  4. Zusammensetzung gemäß einem der Ansprüche 1 bis 3, die außerdem ein pharmazeutisch annehmbares Verdünnungsmittel umfasst.
  5. Zusammensetzung gemäß Anspruch 4, wobei das pharmazeutisch annehmbare Verdünnungsmittel eine Kochsalzlösung, laktierte Ringers Injektionslösung oder Dextroselösung ist.
  6. Zusammensetzung gemäß Anspruch 1, wobei der pH der Zusammensetzung zwischen 4,0 und 5,0 ist.
  7. Zusammensetzung gemäß Anspruch 6, wobei der pH der Zusammensetzung zwischen 4,2 und 4,8 ist.
  8. Zusammensetzung gemäß einem der Ansprüche 1 bis 7, wobei die Säure HCl ist.
  9. Zusammensetzung gemäß einem der Ansprüche 1 bis 7, wobei die Säure Gentisinsäure ist.
  10. Verfahren zur Herstellung der Tigecyclin-Zusammensetzung gemäß Anspruch 1, umfassend Kombinieren eines der folgenden Kohlenhydrate: Laktose, Mannose, Saccharose oder Glukose, zur Reduzierung der Epimerisierung mit Tigecyclin und Wasser unter Bildung einer Lösung;
    Reduzieren des pHs der Lösung auf zwischen 3,0 und 7,0 mit einer Säure oder einem Puffer, um oxidativen Abbau zu reduzieren, und Lyophilisieren der Lösung zur Trockne.
  11. Verfahren gemäß Anspruch 10, wobei das Kohlenhydrat zur Reduzierung der Epimerisierung Laktose ist.
  12. Verfahren gemäß Anspruch 10, das außerdem Kombinieren der Zusammensetzung, die durch Lyophilisieren der Lösung zur Trockne erhalten wurde, mit physiologischer Kochsalzlösung, laktierter Ringers Injektionslösung oder Dextroselösung umfasst.
  13. Verfahren gemäß Anspruch 10, wobei der pH der Lösung auf zwischen 4,0 und 5,0 reduziert wird.
  14. Verfahren gemäß Anspruch 13, wobei der pH der Lösung auf zwischen 4,2 und 4,8 reduziert wird.
  15. Verfahren, wie es in einem der Ansprüche 10 bis 14 beansprucht wird, wobei die Säure 1,0 N HCl ist.
  16. Verfahren, wie es in einem der Ansprüche 10 bis 14 beansprucht wird, wobei die Säure Gentisinsäure ist.
  17. Pharmazeutische Zusammensetzung gemäß einem der Ansprüche 1 bis 9.
EP06737947.9A 2005-03-14 2006-03-13 Tigecyclin-zusammensetzungen und herstellungsverfahren dafür Expired - Lifetime EP1858488B2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI200631658T SI1858488T2 (sl) 2005-03-14 2006-03-13 Kompozicije tigeciklina in metode za pripravo
PL06737947.9T PL1858488T5 (pl) 2005-03-14 2006-03-13 Kompozycje tygecykliny i sposoby wytwarzania
CY20131100905T CY1114504T1 (el) 2005-03-14 2013-10-16 Συνθεσεις τιγεκυκλινης και μεθοδοι παρασκευης

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66103005P 2005-03-14 2005-03-14
PCT/US2006/008827 WO2006099258A1 (en) 2005-03-14 2006-03-13 Tigecycline compositions and methods of preparation

Publications (3)

Publication Number Publication Date
EP1858488A1 EP1858488A1 (de) 2007-11-28
EP1858488B1 true EP1858488B1 (de) 2013-09-11
EP1858488B2 EP1858488B2 (de) 2022-07-20

Family

ID=36648809

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06737947.9A Expired - Lifetime EP1858488B2 (de) 2005-03-14 2006-03-13 Tigecyclin-zusammensetzungen und herstellungsverfahren dafür

Country Status (25)

Country Link
US (5) US7879828B2 (de)
EP (1) EP1858488B2 (de)
JP (1) JP4972081B2 (de)
KR (2) KR101354093B1 (de)
CN (2) CN102512429A (de)
AR (2) AR053827A1 (de)
AU (1) AU2006223226B2 (de)
BR (1) BRPI0608464A2 (de)
CA (1) CA2602089C (de)
CR (1) CR9416A (de)
CY (1) CY1114504T1 (de)
DK (1) DK1858488T4 (de)
ES (1) ES2434944T5 (de)
GT (1) GT200600112A (de)
HN (1) HN2006011218A (de)
IL (1) IL185924A (de)
MX (1) MX2007010983A (de)
NO (1) NO20074278L (de)
PE (1) PE20061107A1 (de)
PL (1) PL1858488T5 (de)
PT (1) PT1858488E (de)
RU (1) RU2428190C2 (de)
TW (1) TW200700092A (de)
WO (1) WO2006099258A1 (de)
ZA (1) ZA200707831B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021063468A1 (en) 2019-10-02 2021-04-08 Anfarm Hellas S.A. Stable parenteral pharmaceutical composition containing tigecycline and process for the preparation thereof

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1858488B2 (de) 2005-03-14 2022-07-20 Wyeth LLC Tigecyclin-zusammensetzungen und herstellungsverfahren dafür
AR057649A1 (es) * 2005-05-27 2007-12-12 Wyeth Corp Formas solidas cristalinas de tigeciclina y metodos para preparar las mismas
PE20070072A1 (es) * 2005-06-16 2007-02-25 Wyeth Corp Proceso de manufactura para tigeciclina como polvo reconstituible
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
EP2007713A2 (de) * 2006-04-17 2008-12-31 Teva Pharmaceutical Industries Ltd Isolierung von tetracyclinderivaten
PT2016045E (pt) * 2006-04-24 2015-02-05 Teva Pharma Forma cristalina de tigeciclina e processos para a sua preparação
US8198470B2 (en) * 2006-04-24 2012-06-12 Teva Pharmaceutical Industries Ltd. Crystalline form II of tigecycline and processes for preparation thereof
FR2910812B1 (fr) * 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
PT2271348T (pt) * 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
US9107929B2 (en) 2008-05-01 2015-08-18 Ranbaxy Laboratories Limited Stable parenteral formulations of tigecycline
WO2010017273A2 (en) * 2008-08-06 2010-02-11 Wyeth Tigecycline formulations
CN102138925B (zh) * 2010-01-29 2014-06-25 正大天晴药业集团股份有限公司 替加环素组合物及其制备方法
MX347919B (es) * 2010-05-12 2017-05-17 Rempex Pharmaceuticals Inc * Composiciones de tetraciclina.
CN108195965B (zh) 2011-06-07 2021-02-23 旭化成制药株式会社 含pth肽冷冻干燥制剂的检査方法及包含该含pth肽冷冻干燥制剂的医药品的制造方法
CN102391148B (zh) * 2011-10-24 2014-01-08 江苏奥赛康药业股份有限公司 一种高纯度替加环素的合成方法
CN103315947B (zh) 2012-03-22 2016-01-20 上海汇伦生命科技有限公司 一种注射用替加环素组合物
CN103356662B (zh) * 2012-03-27 2015-11-25 浙江医药股份有限公司新昌制药厂 注射用替加环素组合物及其制备方法
CN102641249A (zh) * 2012-05-06 2012-08-22 江苏奥赛康药业股份有限公司 一种替加环素组合物的制备方法
CN103417498B (zh) * 2012-05-18 2017-09-12 山东新时代药业有限公司 一种替加环素冻干粉针剂的制备方法
CN102697739B (zh) * 2012-05-31 2014-10-29 丽珠医药集团股份有限公司 一种减少替加环素差向异构体化的粉针剂制备方法
CN102911077B (zh) * 2012-11-12 2015-01-07 成都百裕科技制药有限公司 4r-替加环素的制备方法
IN2013MU01127A (de) 2013-03-26 2015-05-01 Astron Res Ltd
WO2014167575A2 (en) 2013-03-26 2014-10-16 Astron Research Limited Stable tigecycline composition
CN104107170A (zh) * 2013-04-22 2014-10-22 上海汇伦生命科技有限公司 一种替加环素组合物
US20140323443A1 (en) * 2013-04-30 2014-10-30 Fresenius Kabi Usa, Llc Tigecycline formulations
WO2015071299A2 (en) 2013-11-12 2015-05-21 Galenicum Health S.L. Stable pharmaceutical compositions
NO2723977T3 (de) 2014-03-19 2018-03-10
CN105079816B (zh) * 2015-08-17 2018-09-07 江苏豪森药业集团有限公司 替加环素药物组合物及其制备方法
CN108653216B (zh) * 2018-05-28 2020-12-18 福安药业集团湖北人民制药有限公司 注射用替加环素
CN113582870A (zh) * 2020-05-01 2021-11-02 复旦大学附属华山医院 一种恢复替加环素抗菌活性的方法
IT202100031133A1 (it) 2021-12-13 2023-06-13 Zambon Spa Composizione farmaceutica comprendente tigeciclina

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH225704A (de) 1942-01-06 1943-02-15 Schlotterbeck Automobile Aktie Holzgasgenerator.
GB901107A (en) 1959-06-29 1962-07-11 Pfizer Therapeutic composition and method of preparing same
US3026248A (en) 1959-09-11 1962-03-20 Pfizer & Co C Thioglycerol and formaldehyde sulfoxylate stabilized tetracycline antibiotics in polyhydric alcohol solvents
US3106512A (en) 1961-07-19 1963-10-08 Olin Mathieson Stabilization of tetracycline base in dry form with glucono delta lactone
US3145228A (en) 1962-09-06 1964-08-18 Pfizer & Co C 5-alkoxy-and 5-benzyloxy-tetracycline, derivatives and analogues thereof
US3219529A (en) 1962-10-04 1965-11-23 American Cyanamid Co Stable tetracycline solutions
US4038315A (en) 1972-05-11 1977-07-26 American Cyanamid Company Isolation and recovery of calcium chloride complex of 7-dimethylamino-6-dimethyl l-6-deoxytetracycline hydrochloride
DE2748132A1 (de) 1977-10-27 1979-05-03 Behringwerke Ag Stabilisator fuer polysaccharid
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4678812A (en) 1986-05-30 1987-07-07 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
DE69127591T2 (de) † 1990-06-22 1998-01-22 Canon Kk Vorrichtung und Verfahren zum Verarbeiten von Bildern
US5494903A (en) 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5675030A (en) † 1994-11-16 1997-10-07 American Cyanamid Company Method for selective extracting a 7-(hydrogen or substituted amino)-9- (substituted glycyl) amido!-6-demethyl-6-deoxytetracycline compound
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US5908838A (en) 1998-02-19 1999-06-01 Medics Pharmaceutical Corporation Method for the treatment of acne
EP1212050B1 (de) 1999-09-14 2006-12-06 Mucosal Therapeutics LLC Zusammensetzungen, welche tetracycline enthalten, zur behandlung oder verhinderung von mukositis
WO2002012170A1 (en) 2000-08-04 2002-02-14 Trustees Of Tufts College 8-substituted tetracycline compounds
AU2002241849A1 (en) 2001-01-11 2002-07-24 Board Of Regents, The University Of Texas System Dosage adjustement for antibiotics
EP1401402B1 (de) 2001-05-29 2016-09-07 Takeda Pharmaceuticals U.S.A., Inc. Erhöhung der oralen bioverfügbarkeit einer nicht-emulgierten formulierung cefditoren pivoxil mit lecithin
EP1408987B1 (de) 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracyclin-verbindungen mit therapeutischen zielaktivitäten
US20030171340A1 (en) 2002-02-07 2003-09-11 Jenefir Isbister Methods of disease treatment using metal-complexed tetracycline antibiotics
CN1390550A (zh) 2002-07-25 2003-01-15 于航 盐酸米诺环素冻干粉针剂及其制备方法
JP4686189B2 (ja) 2002-10-24 2011-05-18 パラテック ファーマシューティカルズ インコーポレイテッド Ｒｎａを調節するための置換テトラサイクリン化合物の使用方法
WO2004078111A2 (en) 2003-03-06 2004-09-16 Ranbaxy Laboratories Limited Extended release minocycline compositions and processes for their preparation
CN1568999A (zh) 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
US20050148553A1 (en) 2003-09-05 2005-07-07 Testa Raymond T. Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis
GB2414668B (en) 2004-06-03 2009-07-29 Dexcel Ltd Tetracycline modified release delivery system
CN101039679A (zh) 2004-10-28 2007-09-19 惠氏公司 替加环素和地高辛的共投与
EP1858488B2 (de) 2005-03-14 2022-07-20 Wyeth LLC Tigecyclin-zusammensetzungen und herstellungsverfahren dafür
AR057034A1 (es) 2005-05-27 2007-11-14 Wyeth Corp Metodos para purificar tigeciclina
EP3003273A1 (de) † 2013-05-31 2016-04-13 Xellia Pharmaceuticals ApS Verfahren zur stabilisierung von tigecyclin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MURALIDHARAN GOPAL ET AL: "Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 49, no. 1, 1 January 2005 (2005-01-01), pages 220 - 229, XP002425287, ISSN: 0066-4804, DOI: 10.1128/AAC.49.1.220-229.2005 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021063468A1 (en) 2019-10-02 2021-04-08 Anfarm Hellas S.A. Stable parenteral pharmaceutical composition containing tigecycline and process for the preparation thereof

Also Published As

Publication number Publication date
KR20080002828A (ko) 2008-01-04
US10588975B2 (en) 2020-03-17
AR053827A1 (es) 2007-05-23
WO2006099258A8 (en) 2007-10-04
CA2602089C (en) 2013-04-30
RU2007131396A (ru) 2009-04-20
ES2434944T5 (es) 2022-10-20
KR101354093B1 (ko) 2014-01-24
JP4972081B2 (ja) 2012-07-11
US20110118216A1 (en) 2011-05-19
ZA200707831B (en) 2011-02-23
US20060247181A1 (en) 2006-11-02
GT200600112A (es) 2006-11-29
US9694078B2 (en) 2017-07-04
CN102512429A (zh) 2012-06-27
EP1858488A1 (de) 2007-11-28
DK1858488T4 (da) 2022-09-12
CN101132775A (zh) 2008-02-27
TW200700092A (en) 2007-01-01
ES2434944T3 (es) 2013-12-18
CY1114504T1 (el) 2016-10-05
AU2006223226A1 (en) 2006-09-21
AU2006223226B2 (en) 2012-03-15
CA2602089A1 (en) 2006-09-21
US20160144036A1 (en) 2016-05-26
AR109500A2 (es) 2018-12-19
PL1858488T5 (pl) 2024-01-03
HN2006011218A (es) 2008-09-17
DK1858488T3 (da) 2013-11-04
US20170266290A1 (en) 2017-09-21
WO2006099258A1 (en) 2006-09-21
MX2007010983A (es) 2007-09-19
PL1858488T3 (pl) 2014-01-31
RU2428190C2 (ru) 2011-09-10
NO20074278L (no) 2007-11-20
US8975242B2 (en) 2015-03-10
JP2008533146A (ja) 2008-08-21
US9254328B2 (en) 2016-02-09
IL185924A0 (en) 2008-01-06
US20150141379A1 (en) 2015-05-21
BRPI0608464A2 (pt) 2010-01-05
EP1858488B2 (de) 2022-07-20
IL185924A (en) 2014-05-28
CR9416A (es) 2008-03-06
US7879828B2 (en) 2011-02-01
KR20130122988A (ko) 2013-11-11
PT1858488E (pt) 2013-11-18
PE20061107A1 (es) 2006-12-08

Similar Documents

Publication Publication Date Title
EP1858488B2 (de) Tigecyclin-zusammensetzungen und herstellungsverfahren dafür
US20120277197A1 (en) Tigecycline formulations
US9107929B2 (en) Stable parenteral formulations of tigecycline
US20170196899A1 (en) Stable pharmaceutical compositions
HK1171948A (en) Tigecycline compositions and methods of preparation
US20140323443A1 (en) Tigecycline formulations
EP3302494A1 (de) Gefriergetrocknete parenterale zusammensetzung von tigecyclin und verfahren zur herstellung davon
EP2978426B1 (de) Stabile tigecyclinzusammensetzung
WO2021063468A1 (en) Stable parenteral pharmaceutical composition containing tigecycline and process for the preparation thereof
CN104107170A (zh) 一种替加环素组合物
WO2026022215A1 (en) Lyophilized formulations of rifabutin
US20260137753A1 (en) Daptomycin compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070814

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1110532

Country of ref document: HK

17Q First examination report despatched

Effective date: 20090402

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130506

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 631223

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20131029

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006038357

Country of ref document: DE

Effective date: 20131107

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20131111

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2434944

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20131218

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20130402139

Country of ref document: GR

Effective date: 20131118

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E008635

Country of ref document: EE

Effective date: 20131111

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: WYETH LLC

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 15601

Country of ref document: SK

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: HOLLATZ, CHRISTIAN

Effective date: 20140611

Opponent name: DF-MP DOERRIES FRANK-MOLNIA & POHLMAN PATENTANWAEL

Effective date: 20140610

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: PENTAFARMA S.A.

Effective date: 20140611

Opponent name: HOLLATZ, CHRISTIAN

Effective date: 20140611

R26 Opposition filed (corrected)

Opponent name: TAYLOR WESSING LLP

Effective date: 20140611

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602006038357

Country of ref document: DE

Effective date: 20140610

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E020344

Country of ref document: HU

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1110532

Country of ref document: HK

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: HOLLATZ, CHRISTIAN

Effective date: 20140611

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

26 Opposition filed

Opponent name: HOLLATZ, CHRISTIAN

Effective date: 20140611

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130911

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PLAY Examination report in opposition despatched + time limit

Free format text: ORIGINAL CODE: EPIDOSNORE2

PLBC Reply to examination report in opposition received

Free format text: ORIGINAL CODE: EPIDOSNORE3

PLAP Information related to despatch of examination report in opposition + time limit deleted

Free format text: ORIGINAL CODE: EPIDOSDORE2

PLAT Information related to reply to examination report in opposition deleted

Free format text: ORIGINAL CODE: EPIDOSDORE3

PLAY Examination report in opposition despatched + time limit

Free format text: ORIGINAL CODE: EPIDOSNORE2

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20210224

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20210210

Year of fee payment: 16

Ref country code: LV

Payment date: 20210210

Year of fee payment: 16

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20220720

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602006038357

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006038357

Country of ref document: DE

Owner name: WYETH LLC (N.D.GES.D. STAATES DELAWARE), NEW Y, US

Free format text: FORMER OWNER: WYETH LLC, MADISON, N.J., US

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006038357

Country of ref document: DE

Owner name: WYETH LLC, NEW YORK, US

Free format text: FORMER OWNER: WYETH LLC, MADISON, N.J., US

REG Reference to a national code

Ref country code: HU

Ref legal event code: HC9C

Owner name: WYETH LLC, US

Free format text: FORMER OWNER(S): WYETH LLC, US

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

Effective date: 20220908

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: WYETH LLC; US

Effective date: 20220811

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20220313

REG Reference to a national code

Ref country code: EE

Ref legal event code: LD4A

Ref document number: E008635

Country of ref document: EE

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2434944

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20221020

REG Reference to a national code

Ref country code: SK

Ref legal event code: T5

Ref document number: E 15601

Country of ref document: SK

Ref country code: GR

Ref legal event code: EP

Ref document number: 20220401712

Country of ref document: GR

Effective date: 20221010

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220313

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220313

REG Reference to a national code

Ref country code: LU

Ref legal event code: HC

Owner name: WYETH LLC; US

Free format text: FORMER OWNER: WYETH LLC

Effective date: 20230317

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: WYETH LLC; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), OTHER; FORMER OWNER NAME: WYETH LLC

Effective date: 20230327

REG Reference to a national code

Ref country code: SK

Ref legal event code: TC4A

Ref document number: E 15601

Country of ref document: SK

Owner name: WYETH LLC, NEW YORK, NY, US

Effective date: 20230419

REG Reference to a national code

Ref country code: HU

Ref legal event code: HC9C

Owner name: WYETH LLC, US

Free format text: FORMER OWNER(S): WYETH LLC, US; WYETH LLC, US

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602006038357

Country of ref document: DE

Owner name: WYETH LLC (N.D.GES.D. STAATES DELAWARE), NEW Y, US

Free format text: FORMER OWNER: WYETH LLC, NEW YORK, NY, US

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230411

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: WYETH LLC; US

Effective date: 20230519

REG Reference to a national code

Ref country code: EE

Ref legal event code: HE1A

Ref document number: E008635

Country of ref document: EE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20241220

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20241227

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20250212

Year of fee payment: 20

Ref country code: NL

Payment date: 20250212

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20250310

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20250224

Year of fee payment: 20

Ref country code: DE

Payment date: 20250210

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20250225

Year of fee payment: 20

Ref country code: FI

Payment date: 20250225

Year of fee payment: 20

Ref country code: RO

Payment date: 20250218

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20250303

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250224

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20250213

Year of fee payment: 20

Ref country code: GR

Payment date: 20250224

Year of fee payment: 20

Ref country code: AT

Payment date: 20250224

Year of fee payment: 20

Ref country code: EE

Payment date: 20250210

Year of fee payment: 20

Ref country code: BE

Payment date: 20250212

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250210

Year of fee payment: 20

Ref country code: CZ

Payment date: 20250212

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250213

Year of fee payment: 20

Ref country code: IT

Payment date: 20250311

Year of fee payment: 20

Ref country code: SK

Payment date: 20250210

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20250219

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250409

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250401

Year of fee payment: 20

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 631223

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221005

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20250211

Year of fee payment: 20

REG Reference to a national code

Ref country code: CH

Ref legal event code: H14

Free format text: ST27 STATUS EVENT CODE: U-0-0-H10-H14 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260313

Ref country code: DE

Ref legal event code: R071

Ref document number: 602006038357

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20260313

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20260312

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20260313

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20260312

REG Reference to a national code

Ref country code: SK

Ref legal event code: MK4A

Ref document number: E 15601

Country of ref document: SK

Expiry date: 20260313

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20260313

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20260324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20260313

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 631223

Country of ref document: AT

Kind code of ref document: T

Effective date: 20260313

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20260313